Treatment-Free Remission After Second-Line Nilotinib Treatment
Authors: François-Xavier Mahon, Timothy P. Hughes
Journal: Annals of Internal Medicine (2018)

Letters2 October 2018Treatment-Free Remission After Second-Line Nilotinib TreatmentFrançois-Xavier Mahon, MD, PhD and Timothy P. Hughes, MDFrançois-Xavier Mahon, MD, PhDCancer Center of Bordeaux, Bordeaux, France (F.M.)Search for more papers by this author and Timothy P. Hughes, MDSouth Australian Health and Medical Research Institute, Adelaide, South Australia, Australia (T.P.H.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/L18-0431 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail IN RESPONSE:Our article reported results from the ENESTop (Treatment-Free Remission After Achieving Sustained MR4.5 on Nilotinib) study, which evaluated treatment-free remission in patients with CML in chronic phase treated with second-line nilotinib after frontline imatinib therapy; both of these agents are BCR-ABL1 TKIs. Ms. Bansal and colleagues note that thyroid dysfunction has been observed in patients receiving TKIs and describe a retrospective study (1) reporting thyroid dysfunction in patients with CML who received BCR-ABL1 TKIs, including nilotinib. In that study, Kim and associates (1) found that thyroid dysfunction was most often transient and not associated with clinical symptoms and ...References1. Kim TD, Schwarz M, Nogai H, Grille P, Westermann J, Plöckinger U, et al. Thyroid dysfunction caused by second-generation tyrosine kinase inhibitors in Philadelphia chromosome-positive chronic myeloid leukemia. Thyroid. 2010;20:1209-14. [PMID: 20929406] doi:10.1089/thy.2010.0251 CrossrefMedlineGoogle Scholar2. Mashhadi MA, Kaykhaei MA, Mohammadi M, Hashemi M, Mohamadi Fatide T. Imatinib therapy in chronic myelogenous leukemia and thyroid function tests. Int J Hematol Oncol Stem Cell Res. 2014;8:20-3. [PMID: 25642304] MedlineGoogle Scholar3. Yoshizato T, Nannya Y, Yoshiki Y, Nakamura F, Imai Y, Ichikawa M, et al. Nilotinib-induced hypothyroidism in a patient with chronic myeloid leukemia. Int J Hematol. 2011;93:400-2. [PMID: 21347645] doi:10.1007/s12185-011-0790-2 CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: Cancer Center of Bordeaux, Bordeaux, France (F.M.)South Australian Health and Medical Research Institute, Adelaide, South Australia, Australia (T.P.H.)Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M17-1094. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoTreatment-Free Remission After Second-Line Nilotinib Treatment in Patients With Chronic Myeloid Leukemia in Chronic Phase François-Xavier Mahon , Carla Boquimpani , Dong-Wook Kim , Noam Benyamini , Nelma Cristina D. Clementino , Vasily Shuvaev , Sikander Ailawadhi , Jeffrey Howard Lipton , Anna G. Turkina , Raquel De Paz , Beatriz Moiraghi , Franck E. Nicolini , Jolanta Dengler , Tomasz Sacha , Naoto Takahashi , Rafik Fellague-Chebra , Sandip Acharya , Stephane Wong , Yu Jin , and Timothy P. Hughes Treatment-Free Remission After Second-Line Nilotinib Treatment Arpana Bansal , Sarah Jaroudi , Meredith Gavin , and Alan N. Peiris Metrics Cited byPhase 2 study of bosutinib in Japanese patients with newly diagnosed chronic phase chronic myeloid leukemia 2 October 2018Volume 169, Issue 7Page: 510KeywordsChronic myelocytic leukemiaDisclosureHyperthyroidismHypothyroidismPatientsProspective studiesRetrospective studiesSafetyThyroid ePublished: 2 October 2018 Issue Published: 2 October 2018 Copyright & PermissionsCopyright © 2018 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...